echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Puli Pharmaceutical 500mg Levofloxacin Tablets Obtained Drug Registration Approval

    Puli Pharmaceutical 500mg Levofloxacin Tablets Obtained Drug Registration Approval

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of April 18, Puli Pharmaceuticals (300630.
    SZ) issued an announcement stating that Zhejiang Puli Pharmaceutical Co.
    , Ltd.
    , a wholly-owned subsidiary of the company, had recently received the 500mg Levofloxacin Tablets "Drug Registration Certificate" ( Category 4 generic drugs).

    Levofloxacin (levofloxacin, LVLX) is the levofloxacin optical isomer of the fluoroquinolone drug ofloxacin, and its antibacterial activity in vitro is twice that of ofloxacin.
    Because of its strong antibacterial effect, broad antibacterial spectrum, and a positive antibacterial effect, it is currently the first-line clinical anti-infection drug.
    It can be used to treat adult (≥18 years old) infections caused by designated susceptible bacteria.
    Levofloxacin was developed by Daiichi Pharmaceutical (Daiichi Sankyo Co.
    , Ltd.
    ) and has been listed in more than 40 countries around the world.
    In China, the Daiichi Sankyo Pharmaceutical (Beijing) Co.
    , Ltd.
    's levofloxacin tablets have been approved, the trade name is Kolabit, and the specifications: 0.
    1g and 0.
    5g.

    Zhejiang Puli's levofloxacin tablets have been submitted for registration in the European Union (Netherlands and Germany) and China after the start of research and development.
    They are co-production products and have been included in the priority review category.
    Among them, another specification of 250mg developed in the same period has also obtained the "Drug Registration Certificate" issued by the State Drug Administration in February 2021, and has successfully entered the national drug collection catalog.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.